In its scientific opinion, the Authority also noted that its conclusion on the safety of the novel food was based on the bioavailability study in rats, the in vitro bacterial reverse mutation assay, the in vivo micronucleus test, and the randomised, placebo-controlled human study, without which it could not have assessed the novel food and reached its conclusion.
Recital 9, Regulation (EU) 2024/2694
In forcesince 17 Oct 2024